 | Up a level |
Metzelder, S K; Schroeder, T; Finck, A; Scholl, S; Fey, M; Götze, K; Linn, Y C; Kröger, M; Reiter, A; Salih, H R; Heinicke, T; Stuhlmann, R; Müller, L; Giagounidis, A; Meyer, R G; Brugger, W; Vöhringer, M; Dreger, P; Mori, M; Basara, N; ... (2012). High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia, 26(11), pp. 2353-2359. Basingstoke: Nature Publishing Group 10.1038/leu.2012.105
Fey, M; Dreyling, M (2009). Acute myeloblastic leukemia in adult patients: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of oncology, 20 Suppl 4, pp. 100-101. Oxford: Oxford University Press 10.1093/annonc/mdp141
Fey, M; Dreyling, M (2008). Acute myeloblastic leukemia in adult patients: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of oncology, 19 Suppl 2, ii58-9. Oxford: Oxford University Press 10.1093/annonc/mdn089
Laurencet, F; Ballabeni, P; Rufener, B; Hess, U; Cerny, T; Fey, M; Luthi, JM; Plancherel, C; Zulian, GB; Swiss, Group for Clinical Research (SAKK) (2007). The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas. Acta haematologica, 117(1), pp. 40-7. Basel: Karger 10.1159/000096787
Leyvraz, S; Zweifel, M; Jundt, G; Lissoni, A; Cerny, T; Sessa, C; Fey, M; Dietrich, D; Honegger, HP; Swiss, Group for Clinical Cancer Research (2006). Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. Annals of oncology, 17(4), pp. 646-51. Oxford: Oxford University Press 10.1093/annonc/mdl020
de Botton, S; Sanz, MA; Chevret, S; Dombret, H; Martin, G; Thomas, X; Mediavilla, JD; Recher, C; Ades, L; Quesnel, B; Brault, P; Fey, M; Wandt, H; Machover, D; Guerci, A; Maloisel, F; Stoppa, AM; Rayon, C; Ribera, JM; Chomienne, C; ... (2006). Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia, 20(1), pp. 35-41. Basingstoke: Nature Publishing Group 10.1038/sj.leu.2404006
